111 related articles for article (PubMed ID: 38715787)
1. Corrigendum: Targeting JUN, CEBPB and HDAC3: a novel strategy to overcome drug resistance in hypoxic glioblastoma.
Gao Y; Liu B; Feng L; Sun B; He S; Yang Y; Wu G; E G; Liu C; Gao Y; Zhang E; Zhu B
Front Oncol; 2024; 14():1392899. PubMed ID: 38715787
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum: Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
Gao Y; Liu B; Feng L; Sun B; He S; Yang Y; Wu G; E G; Liu C; Gao Y; Zhang E; Zhu B
Front Oncol; 2020; 10():644. PubMed ID: 32411606
[TBL] [Abstract][Full Text] [Related]
3. Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
Gao Y; Liu B; Feng L; Sun B; He S; Yang Y; Wu G; E G; Liu C; Gao Y; Zhang E; Zhu B
Front Oncol; 2019; 9():33. PubMed ID: 30775317
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide.
Llaguno-Munive M; León-Zetina S; Vazquez-Lopez I; Ramos-Godinez MDP; Medina LA; Garcia-Lopez P
Front Oncol; 2021; 11():675806. PubMed ID: 33828996
[TBL] [Abstract][Full Text] [Related]
5. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease.
Di Villeneuve L; Souza IL; Tolentino FDS; Ferrarotto R; Schvartsman G
Front Oncol; 2021; 11():669486. PubMed ID: 33898325
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma.
Cheng F; Zhang P; Xiao Q; Li Y; Dong M; Wang H; Kuang D; He Y; Duan Q; Mao F; Wang B; Guo D
Front Oncol; 2020; 10():591112. PubMed ID: 33102241
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum: Machine Learning-Based Analysis of Magnetic Resonance Radiomics for the Classification of Gliosarcoma and Glioblastoma.
Qian Z; Zhang L; Hu J; Chen S; Chen H; Shen H; Zheng F; Zang Y; Chen X
Front Oncol; 2021; 11():774369. PubMed ID: 34737968
[TBL] [Abstract][Full Text] [Related]
9. Corrigendum: MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways.
Zhang X; Wang J; Wang Y; Liu G; Li H; Yu J; Wu R; Liang J; Yu R; Liu X
Front Oncol; 2022; 12():911817. PubMed ID: 35530328
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: PHF20 promotes glioblastoma cell malignancies through a
Ma Q; Long W; Xing C; Jiang C; Su J; Wang HY; Liu Q; Wang R
Front Oncol; 2023; 13():1157694. PubMed ID: 37035210
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum: Cytotoxic Effects of Arsenite in Combination With Gamabufotalin Against Human Glioblastoma Cell Lines.
Yuan B; Xu K; Shimada R; Li J; Hayashi H; Okazaki M; Takagi N
Front Oncol; 2021; 11():778834. PubMed ID: 34692557
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum: Decreased DUSP26 Expression Promotes Malignant Behavior in Glioblastoma Cells
Chen J; Zeng Y; Wu R; Xuan Y; Jiang M; Teng H
Front Oncol; 2021; 11():676647. PubMed ID: 33928040
[TBL] [Abstract][Full Text] [Related]
13. Corrigendum: Highly invasive fluorescent/bioluminescent patient-derived orthotopic model of glioblastoma in mice.
Yuzhakova D; Kiseleva E; Shirmanova M; Shcheslavskiy V; Sachkova D; Snopova L; Bederina E; Lukina M; Dudenkova V; Yusubalieva G; Belovezhets T; Matvienko D; Baklaushev V
Front Oncol; 2022; 12():1040637. PubMed ID: 36248972
[TBL] [Abstract][Full Text] [Related]
14. Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features.
Li M; Ren X; Dong G; Wang J; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Yu K; Lin S
Front Oncol; 2021; 11():700599. PubMed ID: 34094991
[TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Glioblastoma survival is associated with distinct proteomic alteration signatures post chemoirradiation in a large-scale proteomic panel.
Krauze AV; Sierk M; Nguyen T; Chen Q; Yan C; Hu Y; Jiang W; Tasci E; Zgela TC; Sproull M; Mackey M; Shankavaram U; Meerzaman D; Camphausen K
Front Oncol; 2024; 14():1348105. PubMed ID: 38544831
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
Front Oncol; 2020; 10():684. PubMed ID: 32426288
[TBL] [Abstract][Full Text] [Related]
17. Erratum: Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Frontiers Production Office
Front Oncol; 2022; 12():952053. PubMed ID: 35747832
[TBL] [Abstract][Full Text] [Related]
18. Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of methe Phase 3 EF-14 Clinical Trial.
Ram Z; Kim CY; Hottinger AF; Idbaih A; Nicholas G; Zhu JJ
Front Oncol; 2022; 12():902929. PubMed ID: 35494031
[TBL] [Abstract][Full Text] [Related]
19. Corrigendum: CircHIPK3 Promotes Metastasis of Gastric Cancer
Jin Y; Che X; Qu X; Li X; Lu W; Wu J; Wang Y; Hou K; Li C; Zhang X; Zhou J; Liu Y
Front Oncol; 2021; 11():783320. PubMed ID: 34869038
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum: Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022.
Liu J; Ma J; Zhang J; Li C; Yu B; Choe HC; Ding K; Zhang L; Zhang L
Front Oncol; 2023; 13():1228879. PubMed ID: 37324024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
